CTOs on the Move

Senti Bio

www.sentibio.com

 
Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. To accomplish this mission, we are building a synthetic biology platform that could enable us to program next-generation cell and gene therapies with what we refer to as “gene circuits”. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, are intended to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell and gene therapies in order to enhance ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.sentibio.com
  • 2 Corporate Drive First Floor
    South San Francisco, CA USA 94080
  • Phone: 510.520.8691

Executives

Name Title Contact Details
Philip Lee
 Co-Founder and Chief Technology Officer Profile

Funding

Senti Bio raised $53M on 02/27/2018

Similar Companies

Alta Medical Management

Alta Medical Management is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PreventionGenetics

Founded in 2004 and located in Marshfield, Wisconsin, PreventionGenetics is a CLIA and ISO 15189:2012 accredited clinical DNA testing laboratory.

TrovaGene

Trovagene is a molecular diagnostics company providing precise, noninvasive urine and blood testing for detecting and monitoring oncogene mutations. By utilizing proprietary technology that analyzes circulating tumor DNA, Trovagene testing offers critical data that may help inform cancer treatment decisions, giving physicians and patients monitoring options beyond biopsy or imaging.

Global BioChem

Global BioChem is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Connect Biopharma

Connect Biopharma (Nasdaq: CNTB) is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research. With operations and expertise in China, the United States and Australia and clinical development activities in those geographies as well as Europe, Connect Biopharma is building a rich pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent drug candidates against immune targets. Our two most advanced clinical-stage programs include highly differentiated product candidates against validated targets.